A novel missense activating mutation in the extracellular calcium-sensing receptor (CaSR) is reported in this work. It was identified in three related subjects with the phenotypic features of autosomal dominant hypocalcemia (ADH). The proband, a 27-year-old woman, diagnosed as having hypoparathyroidism at 7 years of age and a history of seizures, showed the highest penetrance of the mutation. The remaining two affected members presented asymptomatic chronic hypocalcemia despite severe hypoparathyroidism associated with high levels of serum phosphate and calcium urinary excretion. The missense mutation (Glu 604 Lys) affected an amino acid residue in the C terminus of the cysteine-rich domain of the extracellular amino-terminal domain, which seems to be required for the coupling of ligand binding to the activation of intracellular signaling pathways. This genetic change cosegregated with hypocalcemia in all the individuals where the mutation was found. As parathyroid hormone (PTH) secretion is the regulatory target of the CaSR, polymorphism analysis of the PTH gene was carried out. PTH polymorphisms were analyzed in the kindred studied. Affected members for the Glu 604 Lys CaSR mutation which also carried the uncommon PTH alleles showed higher penetrance of the mutation, with more severe autosomal dominant hypocalcemia. These results suggested that the PTH gene could act as a modifier locus of ADH, affecting the penetrance of the activating CaSR mutation described.
Introduction
Autosomal dominant hypocalcemia (ADH) is a rare hereditary syndrome characterized by low serum parathyroid hormone (PTH) levels despite hypocalcemia and relative hypercalciuria, leading to nephrolithiasis and nephrocalcinosis, especially after active vitamin D treatment (Winter et al. 1983 , De Campo et al. 1988 . Mutations responsible for a gain-of-function in the calcium-sensing receptor (CaSR) gene and able to inhibit PTH secretion and renal calcium reabsorption are the cause of ADH (Pollak et al. 1994 , Baron et al. 1996 . The clinical presentation of ADH varies from asymptomatic hypocalcemia to neonatal hypocalcemic seizures even in families with the same CaSR gene mutation.
The CaSR was first identified in bovine parathyroid cells and was later found to be expressed in the kidney and other tissues (Brown et al. 1995b) . The human CaSR encodes a polypeptide of 1078 amino acids organized into three domains: a very large (612 amino acids) extracellular domain at the amino-terminus, a transmembrane domain with seven membranespanning helixes characteristic of G proteincoupled receptors and an intracellular (216 amino acids) carboxyl-terminal tail (Brown et al. 1993 , 1995a , Aida et al. 1995 , Garrett et al. 1995 , Brown 2000 . Mutations in this CaSR involving loss of function cause familial benign hypercalcemia, also known as familial hypocalciuric hypercalcemia; those who have this autosomal disorder, generally asymptomatic, have life-long elevations of serum calcium concentrations, together with a low urinary excretion of calcium (Pollak et al. 1993) . On the other hand, heterozygous gain-of-function (activating) mutations are associated with the reverse phenotype -autosomal dominant hypocalcemiaas described previously. To date, 40 inactivating and 25 activating mutations have been identified (Hendy et al. 2000) . These are mostly missense mutations, unevenly distributed throughout the coding region of the CaSR but clustered in two regions: within the first 300 amino acids of the extracellular domain and from amino acids 520 to 881 in or near the transmembrane domain. Residues in the first 300 amino acids of the extracellular domain have been shown to be important for calcium binding to the CaSR and/or dimerization of the receptor (Brauner-Osborne et al. 1999 , Zhang et al. 2001 .
PTH secretion is the regulatory target of the CaSR. Several polymorphisms have been described in the gene encoding PTH, which may influence not only the secretion rate of the hormone in response to the CaSR signaling but also the efficiency of the hormone, as has been shown in bone metabolism studies (Katsumata et al. 2002) and familial isolated hypoparathyroidism (FIH) (Miric & Levine 1992) . This syndrome, characterized by hypocalcemia and hyperphosphatemia due to an inherited deficient secretion of biologically active parathormone, has been related to PTH gene mutations and polymorphisms (Ahn et al. 1986 , Sunthornthepvarakul et al. 1999 . A mutation in the transcription factor GCMB has also been associated with FIH (Ding et al. 2001) . Three major polymorphisms and two mutations have been described in the PTH gene; one of the polymorphisms is located in intron 1, only 15 nucleotides from the start codon (Yamamoto et al. 1997) whilst the remaining two are located in intron 2 and exon 3 (Mullersman et al. 1992) . A mutation in the signal peptide of the preparathyroid hormone gene has also been described (Sunthornthepvarakul et al. 1999) , along with a donor splice site mutation in the first nucleotide of intron 2 (Parkinson et al. 1993) . Although all five genetic variations have been studied in relation to FIH syndrome, no conclusive general results have been defined, thus pointing out the variability of the causes of this condition (Ahn et al. 1986) .
As previously stated, the penetrance of CaSRactivating mutations is extremely variable. To date, no relationship has been found either between activating changes and polymorphisms of the CaSR gene with pathological expression of the mutations (Kanazawa et al. 2000) or with the location of those changes within the CaSR gene (Nagase et al. 2002) . In this work we report a novel activating mutation (Glu 604 Lys) in a Spanish kindred suffering autosomal dominant hypocalcemia that may be modulated by polymorphisms of the PTH gene and thus affecting its clinical presentation.
Materials and methods

Clinical subjects
The proband (subject II.3; Fig. 1 ) was born in 1976 and was diagnosed as having idiopatic hypoparathyroidism at 7 years of age after presenting with seizures. She has been clinically monitored to date. Studies were also conducted on the other four members of her family. The absence of the Glu 604 Lys mutation was verified in 100 unrelated Spaniards by RFLP. The study was approved by the Hospital Universitario Central de Asturias Clinical Ethics Committee. 
Genomic DNA isolation
High molecular weight nuclear DNA was isolated from peripheral blood leukocytes of the proband, the other four family members and 100 normal subjects by standard procedures (Sambrook et al. 1989) .
Amplification, sequence and confirmation of the CaSR mutation
In the proband, all protein-coding exons (2-7) of the CaSR were amplified by PCR using the primer pairs detailed in Table 1 . PCR was performed in 30 cycles using the following steps: denaturation at 95 C for 30 s, annealing at 64 C for 30 s and extension at 72 C for 90 s on a volume of 20 µl. The PCR reactions were carried out in a GeneAmp 9700 PCR system from Applied Biosystems (Foster City, CA, USA). The amplification products were purified and nucleotide sequences of both strands were determined by direct sequencing with an Applied Biosystems 310A automatic sequencer. After finding the Glu 604 Lys mutation in the proband, exon 7 of the CaSR gene of other family members and control subjects was amplified by PCR using the primer pair 5 -GTCTGTGC CACACAATAACTCAC-3 and 5 -CCAAGAAA CCTCTCTGCATTCTC-3 . As the mutation, a replacement of a guanine by an adenine, destroys a recognition site for TaqI (TCGA), this endonuclease was used to digest the amplified 431 bp fragment. The absence of the mutation generates two fragments of 310 and 121 bp, detected by electrophoresis on a 1·2% agarose gel ( Fig. 2A) . These experiments were carried out at least twice and the results were reproducible. Each experiment contained the affected patient's DNA which was heterozygous for the mutation to ensure that all samples were completely digested by restriction enzyme.
PTH polymorphisms analysis
PTH gene polymorphisms were studied by PCR amplification (primers reproduced in Table 1 ) and restriction or direct sequencing analysis was carried out in all the family members. PCR conditions were: denaturation at 95 C for 30 s, annealing at 54 C for 15 s and extension at 72 C for 30 s on a volume of 20 µl. All three polymorphisms described to date were analyzed. For intron 1 polymorphism, a 186 bp DNA fragment was amplified and sequenced. The remaining two PTH gene polymorphisms, located in intron 2 and exon 3 disrupt restriction sites BstBI and DraII respectively; they were determined by amplification of a 609 bp fragment and restriction analysis with the appropriate enzymes. In the case of BstBI, the presence of the restriction site (denoted as B) produces two DNA fragments of 383 and 226 bp, while the presence of the DraII restriction site (denoted as D) produces two fragments of 434 and 175 bp.
Results
DNA sequence analysis of the proband showed a heterozygous single base G-A missense mutation in position 2182 of exon 7 (GenBank U20759), resulting in the amino acid substitution of a glutamic acid by a lysine. The mutation found (Glu 604 Lys), lies at the C terminus of the Cys-rich domain of the extracellular head, only nine residues from the first transmembrane helix.
Once the mutation was found by sequencing the proband's coding regions of the CaSR gene, and taking into account that the G-A transition destroys a TaqI recognizing sequence, this restriction site was used to analyze the other members of the family and 100 unrelated DNA controls. Figure  2A shows that the mutation analysis of the CaSR found three affected members of the family that was studied: I.1, II.1 and the proband II.3. The results are thus consistent with the autosomal dominant inheritance pattern in ADH. None of the unrelated controls was positive for the genetic change, thus confirming its mutation character. Although members I.1 and II.3 were currently in treatment (being the only ones suspected of carrying the mutation), II.1 was also found to posses the genetic change in the CaSR gene. II.1 was undiagnosed, but the analytical results confirmed low calcium serum levels (calcium 6·5 mg/dl), thus confirming the autosomal dominant hypocalcemia determined by the Glu 604 Lys change.
While I.1 and II.1 were asymptomatic, and only low levels of serum calcium and PTH have determined their medical treatment, II.3, on the other hand, was diagnosed with idiopatic hypoparathyroidism at 7 years of age after suffering tetanias caused by hypocalcemia (calcium 6 mg/dl; intact PTH (iPTH),1 pg/ml). Treatment with vitamin D produced a toxic hypercalcemia episode (calcium 15·7 mg/dl), probably due to D3 hypervitaminosis. Lithotripsy was required to eliminate a calcium oxalate kidney stone at 14 years of age and a digestive hemorrhagic episode was treated at 19 years of age.
I.1 was diagnosed with hypocalcemia (calcium 6·5 mg/dl; iPTH 6 pg/ml) after a routine analysis at 54 years of age and has been on calcium, vitamin D, magnesium, potassium and thiazyde treatment without an improvement in the calcemic levels. A review of his clinical records showed an isolated episode of loss of consciousness at 10 years of age, while lithiasis in both kidneys, along with calcification of his cerebral falx and several smooth tissues, are a good indication of a long and severe penetrance of the pathology.
II.1 had remained undiagnosed until the genetic study showed the presence of the CaSR-activating mutation. The biochemical parameters revealed hypocalcemia, low levels of serum PTH and hyperphosphatemia, but none of the related pathological consequences found in both his father and younger sister. Neither I.2 nor II.2 showed any anomalies in their biochemical parameters. Both parents of I.1 are deceased and therefore unavailable for the mutation analysis, but as none had a history of hypocalcemia, it is possible to speculate that the CaSR dominant mutation appeared de novo in I.1.
In order to explain the differences in the clinical presentation among the affected members, a study of the PTH gene variations was performed. The results, shown in Fig. 2B , demonstrated that I.1, II.2 and II.3 presented variation for the polymorphism located 15 nucleotides from the initiation codon (intron 1) and for the BstBI restriction site. All family members were homozygous for the silent polymorphism located in the DraII site of exon 3. Analysis of the signal peptide of the preproparathyroid hormone gene and the donor splice site mutations was also carried out, showing that none of them were present in the kindred (data not shown).
Discussion
The present study demonstrates a novel missense activating mutation (Glu 604 Lys) affecting the CaSR in a Spanish kindred with ADH. The proband has been suffering severe hypocalcemia and hypercalciuria since childhood, while the other affected members of this family showed asymptomatic hypocalcemia with hyperphosphatemia, relative hypercalciuria and low levels of PTH. As these results and the autosomal dominant pattern of inheritance are suggestive of ADH, the molecular studies necessary to establish the diagnosis were conducted. The results suggested that the Glu 604 Lys mutation caused ADH in this family, as the mutation was found in all three hypocalcemic members but in none of the normocalcemic members of the family or in 100 control subjects.
Interestingly, this mutation has also been recently described in an Australian kindred during the elaboration of this work (Tan et al. 2003 (Tan et al. 2003) . To date, 25 activating mutations in the CaSR have been reported, and with the exception of a large deletion in the carboxyl-terminal tail, all are missense mutations (Hendy et al. 2000) . Their location within the CaSR gene is variable as 14 are localized in the extracellular domain (Pollak et al. 1994 , Baron et al. 1996 , Pearce et al. 1996 , De Luca et al. 1997 , Mancilla et al. 1998 , Okazaki et al. 1999 , Conley et al. 2000 , Hendy et al. 2000 , Tan et al. 2003 , six in the transmembrane helixes (Baron et al. 1996 , De Luca et al. 1997 , Watanabe et al. 1998a , Hendy et al. 2000 and two in the extracellular loops within the transmembrane domain (Baron et al. 1996 , Hendy et al. 2000 . Although some authors have pointed out that mutations in the transmembrane helixes might produce more severe hypocalcemia than those present in the extracellular domain (Watanabe et al. 1998b) , no significant relationship has been further demonstrated between mutation location and penetrance of the mutation. The Glu 604 Lys-activating mutation lies in the Cys-rich domain of the extracellular head, which seems to be required for the coupling of ligand binding to the activation of intracellular signaling pathways (Hu et al. 2000) . The activating effect of Glu 604 Lys might therefore arise from a sensitizing effect on signal transmission (Tan et al. 2003) .
In order to explain the clinical differences between family members affected with the activating dominant mutation Glu 604 Lys, polymorphisms of the PTH gene were also analyzed. Only two out of the three PTH polymorphisms were informative, showing that I.1, II.2 and II.3 were heterozygous for a nucleotide variation in both BstBI and intron 1 polymorphisms. I.1 and II.3 were also carriers of the Glu 604 Lys and those with major ADH penetrance. Although none of the BstBI and intron 1 polymorphisms have been associated with drastic effects on PTH expression or efficiency, translated as FIH presentation, both have been associated with differences in bone mineral density, bone dimension and osteoporosis (Almahroos et al. 1987 , Gong et al. 1999 , Hosoi et al. 1999 , Gohda et al. 2002 . I.1 and II.3, carrying both the CaSR mutation and the less favorable allelic form of each polymorphism, are likely to have their CaSRrelated condition worsened due to PTH deficiency. Thus, considering both the CaSR mutation and the polymorphic changes in the PTH gene, it might be speculated that the PTH gene acts as a modifier locus of the ADH condition. Further studies in kindreds presenting this activating mutation or other diseases related to mutations of the CaSR will be required to confirm this hypothesis.
